The use of data from early arthritis clinics for clinical research

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 1, 2009, Pages 117-123

  Aletaha, Daniel ^a   Huizinga, T W J ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

criteria for RA; early arthritis clinics; early diagnosis; early treatment; statistical methods

Indexed keywords

AUTOANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTHRITIS; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL RESEARCH; DATA ANALYSIS; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; GENETIC MARKER; HEALTH EDUCATION; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; MEDICAL DECISION MAKING; PATHOGENESIS; PATIENT GUIDANCE; PRIORITY JOURNAL; REVIEW;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; HUMANS; MODELS, STATISTICAL;

EID: 60749094439     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.11.008     Document Type: Review

References (29)

1. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol 44 Suppl. (1996) 13-22
2. Pincus T., Callahan L.F., Sale W.G., et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27 (1984) 864-872
3. Smolen J.S., and Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 63 3 (2004) 221-225
4. Wilske K.R., and Healey L.A. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol 17 Suppl. 25 (1990) 4-7
5. Fries J.F., Williams C.A., Ramey D., and Bloch D.A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 36 3 (1993) 297-306
6. Fries J.F., Williams C.A., and Bloch D.A. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 34 11 (1991) 1353-1360
7. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 3 (1988) 315-324
8. Silman A.J., and Symmons D.P. Selection of study population in the development of rheumatic disease criteria: comment on the article by the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 38 5 (1995) 722-723
9. van Aken J., van Bilsen J.H., Allaart C.F., et al. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 21 5 Suppl. 31 (2003 Sep-Oct) S100-S105 Review
10. Nielen M.M., van Schaardenburg, Reesink W.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50 (2004) 380-386
11. Emery P., Breedveld F.C., Dougados M., et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 61 4 (2002) 290-297
12. van Dongen H., van Aken J., Lard L.R., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56 5 (2007 May) 1424-1432
13. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146 6 (2007 Mar 20) 406-415
14. van der Helm-van Mil A.H., le C.S., van D.H., et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 56 2 (2007) 433-440
15. Green M., Marzo-Ortega H., McGonagle D., et al. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 42 10 (1999) 2184-2188
16. Harrison B.J., Symmons D.P., Brennan P., et al. Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation. J Rheumatol 23 8 (1996) 1326-1331
17. Bukhari M., Lunt M., Harrison B.J., et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 46 4 (2002) 906-912
18. Visser H., le Cessie S., Vos K., et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46 2 (2002) 357-365
19. van der Helm-van Mil A.H., Detert J., le C.S., et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 58 8 (2008) 2241-2247
20. Aletaha D., Breedveld F.C., and Smolen J.S. The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum 52 11 (2005) 3333-3336
21. Aletaha D., Eberl G., Nell V.P., et al. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 63 10 (2004) 1269-1275
22. Symmons D.P., Bankhead C.R., Harrison B.J., et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 40 11 (1997) 1955-1961
23. Heliovaara M., Aho K., Aromaa A., et al. Smoking and risk of rheumatoid arthritis. J Rheumatol 20 11 (1993) 1830-1835
24. Uhlig T., Hagen K.B., and Kvien T.K. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol 26 1 (1999) 47-54
25. Linn-Rasker S.P., van der Helm-van Mil A.H., van Gaalen F.A., et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65 3 (2006 Mar) 366-371 Epub 2005 Jul 13
26. Kallberg H., Padyukov L., Plenge R.M., et al. Epidemiological Investigation of Rheumatoid Arthritis study group.Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 80 5 (2007 May) 867-875
27. van der Helm-van Mil A.H., and Huizinga T.W. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 10 2 (2008) 205
28. van Oosterhout M., Bajema I., Levarht E.W., et al. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheum 58 1 (2008 Jan) 53-60
29. van Gaalen F.A., van Aken J., Huizinga T.W., et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50 7 (2004 Jul) 2113-2121